Pre-Clinical
Research Data
CyberGXP helps organisations secure pre-clinical research environments without disrupting scientific progress or collaboration.
Pre-clinical research is where pharmaceutical and healthcare innovation begins — and where cyber risk first takes hold.
At this stage, organisations generate highly sensitive research data, proprietary methodologies, and early intellectual property that define future product value and regulatory success. Protecting pre-clinical research data is critical to maintaining data integrity, safeguarding innovation, and ensuring future regulatory readiness.
What You’re Protecting
at the Pre-Clinical Stage
Pre-clinical environments typically include a complex mix of internal teams, external partners, and evolving systems. Cyber risk often emerges before formal GxP controls are fully embedded.
Key assets at risk include:
Research datasets and experimental results
Proprietary compound data and intellectual property
Laboratory systems and instruments
Cloud-based research platforms and analytics tools
Collaborative environments involving academia and third-party partners
These assets are increasingly targeted due to their long-term commercial and strategic value.
Regulatory & GxP Considerations
While pre-clinical research may not yet be fully regulated under GMP, decisions made at this stage directly impact future compliance and inspection outcomes.
CyberGXP helps organisations align early research environments with emerging regulatory expectations, including:
Data integrity principles (ALCOA+)
Secure record retention and traceability
Controlled access to research systems and data
Early alignment with GxP and validation principles
Future audit and inspection readiness
Embedding cyber security early reduces remediation effort and regulatory risk later.
How CyberGXP Supports
Pre-Clinical Research
Our approach is designed to protect innovation without slowing research.
CyberGXP supports pre-clinical environments through:
Research environment cyber risk assessments
Secure access and identity management
Protection of cloud-based research platforms
Third-party and academic collaboration risk management
Data integrity and research system assurance
We focus on proportionate, risk-based controls that scale as your product progresses.
Preparing for
What Comes Next
Organisations that secure pre-clinical research effectively are better positioned to transition into Clinical Trials (Phase I–III), where patient data, regulatory oversight, and operational complexity increase significantly.
Cyber security at this stage should not be retrofitted — it should evolve naturally as part of the product lifecycle.
Secure Your Research
Before Risk Escalates.
If you’re operating in pre-clinical research and want to protect intellectual property, maintain data integrity, and prepare for future regulatory expectations, speak to CyberGXP. We’ll help you reduce risk now — and avoid costly remediation later.